insulin receptor; diabetes mellitus CAVEOLIN (CAV) IS COMPOSED of three subtypes (Cav1, Cav2, and Cav3), and it is a major protein component of caveolae, which are flask-shaped, cell membrane invaginations that are abundantly expressed in adipocytes, myocytes, and endothelial cells (5) . Caveolae accumulate multiple receptors and kinases that are involved in cell growth and proliferation (11, 19) . The net effect of these interactions is the suppression of cellular growth and proliferation signals (5) . Accordingly, it is widely believed that Cav is a potent growth suppressor.
Despite numerous studies demonstrating an important role for Cav in regulating various growth signals, the role of Cav in regulating insulin receptor (IR) signals has remained rather controversial. Some studies have shown a positive association of Cav with IR signals (3, 22) while others have refuted these findings (10) . Nevertheless, it has been proposed that Cav may not inhibit insulin signals, but may be required or even activate this signaling pathway (28) . Mice with a disrupted Cav1 gene, which is most abundantly expressed in adipocytes, showed decreased IR protein expression and developed insulin resistance in fat tissues (7) . Similarly, mice with disrupted Cav3, which is abundantly expressed in the muscles (9) , developed insulin resistance in the skeletal muscles (22) . Furthermore, a previous study used purified proteins to demonstrate that a small peptide derived from Cav stimulated IR kinase activity in vitro; interestingly, this stimulation was more potent with a peptide derived from Cav3 than Cav1 (30) . These findings have suggested that Cav plays an important role in maintaining physiological insulin signals in the major target organs of insulin action, i.e., the liver and fat tissues.
In the present study, we have addressed the role of Cav in the liver. The liver is a major insulin target that expresses only a small amount of endogenous Cav, suggesting that the liver, unlike fat tissues and skeletal muscles, does not require high Cav levels, at least, under normal conditions. We have examined the effect of Cav3 gene transfer to the livers of diabetic obese mice fed a high-fat diet or KKA y mice, a widely used Type 2 diabetic model (17) . We demonstrated that Cav enhances IR signaling in vivo and in vitro. Insulin sensitivity and thus glucose metabolism were markedly improved by Cav3 gene transfer in diabetic mice, as exemplified by increased hepatic glycogen synthesis and improved glucose tolerance test performance.
MATERIALS AND METHODS
Diabetic mouse models. At weaning, mice (3 wk of age) were placed on either a high-fat diet (59% of calories derived from fat) for diabetic obese mice or a normal chow diet (10% of calories derived from fat) for lean normal mice (Oriental Yeast, Tokyo, Japan) for at least 6 mo. Differences in body weight became significant at 5 wk (Fig. 1A) . At 6 mo, fasting blood glucose (FBG) levels were increased approximately threefold (Fig. 1B) and serum triglycerides by 20% (Fig. 1C ) in obese diabetic mice relative to lean normal mice.
KKA y mice were purchased from CLEA Japan (Tokyo, Japan) and used for experiments at 10 wk old. All animals were maintained in accordance with the guidelines of the animal experiment committees of Yokohama City University, and experiments were approved by the Ethical Committee of Animal Experiments of Yokohama City University School of Medicine.
Adenovirus construction and injection into mice. Full-length cDNA encoding rat Cav3 was cloned into the shuttle vector to construct an adenoviral vector harboring Cav3 or green fluorescent protein (GFP; control) using an AdenoX adenovirus construction kit (Clontech, Palo Alto, CA) (11) . An adenovirus titer of 1.0 ϫ 10 7 plaque-forming units (PFU) was sufficient to overexpress Cav3 in the liver to levels equivalent to endogenous Cav3 in the skeletal muscles, where Cav3 is most abundantly expressed, for up to 6 days after viral injection (Fig. 2, A and B) .
Radioligand binding assays and Western blot analysis. Radioligand binding assays for cell surface IR were performed using HepG2 cells and 125 I-labeled insulin as previously described (20, 24) . Immunoblotting of Cav, IR-␤, and its related molecules was performed as previously described (21, 22) .
Immunoprecipitation assays. An in vivo phosphorylation assay for IR-␤ or insulin receptor substrate (IRS) was performed as previously described (22) . After anesthesia was induced with pentobarbital sodium intraperitoneally (100 mg/kg ip), tissues were quickly harvested and stored in liquid nitrogen. Immunoprecipitation of Cav, IR-␤, and its related molecules was performed as we previously described (22) .
Protein fractionation by the sucrose gradient method. Caveolae fractions were separated by the sodium carbonate-based, detergentfree method (26, 30) .
Glucose and insulin tolerance tests. After a 16-h period of fasting, glucose (2 mg/g body wt ip) was injected. FBG levels were determined at 0, 30, 60, 90, and 120 min after injection using a glucometer (22) . For the insulin tolerance test, insulin was injected (0.75 U/kg ip), and then FBG levels were measured (7) .
Measurements of hepatic glycogen synthesis and triglycerides. Glycogen was measured as previously described (27) . Briefly, livers were homogenized in 6 M perchloric acid. The homogenate was boiled for 5 min at 100°C and centrifuged at 10,000 g. Glycogen in the supernatant was precipitated with ethanol and measured by a phenolsulfuric acid reaction. Hepatic triglycerides were extracted as described previously (13) . Briefly, tissues were homogenized in extraction buffer (20 mM Tris, pH 7.3, 1 mM EDTA, and 1 mM ␤-mercaptoethanol), after which chloroform, methanol, and water were added. The mixture was centrifuged at 3,000 g. The lower phase was evaporated and redissolved in isopropanol, and triglyceride concentrations were determined with the GPO-Trinder (Sigma, St. Louis, MO).
Measurements of serum lipids. Total cholesterol and triglycerides were determined as we described previously (22) .
Cell culture. HepG2 cells, a human hepatocellular carcinoma cell line, were cultured in Dulbecco's modified Eagle's medium containing 5% fetal bovine serum and 10% horse serum in a humidified 95% air-5% CO2 incubator.
Inhibition of phosphatase activity by Cav peptides. Phosphatase activity was measured colorimetrically using a commercial assay kit (Calbiochem, San Diego, CA) and purified protein tyrosine phosphatase 1B (PTP1B) (Upstate, Lake Placid, NY) in the presence or absence of the following Cav peptides; for the scaffolding domain Fig. 1 . Generation of obese diabetic mice. A: changes in body weight between obese mice and age (W, weeks)-matched, normal lean mice (n ϭ 31, *P Ͻ 0.05; NS, not significant). B and C: comparison of fasting blood glucose levels (n ϭ 8 -13, *P Ͻ 0.05) (B) and serum triglycerides (n ϭ 4 -5, *P Ͻ 0.05) (C) between lean control (Lean) and obese diabetic (Obese) mice. GAPDH is shown as loading standard. E: expression of molecules involved in insulin receptor (IR) signaling in hepatic tissues after Cav3 or GFP gene transfer. IRS-1 and 2, insulin receptor substrate 1 and 2; PTP1B, protein tyrosine phosphatase 1B; PI3K, phosphatidylinositol 3-kinase. F: sucrose gradient fractionation of liver proteins and immunoblotting of exogenous Cav3, endogenous Cav1, and IR-␤ (lanes 4, 5, and 6, caveolar fractions; lanes 10, 11, and 12, noncaveolar fractions) (SD) peptide: Cav3 (SD-Cav3)-DGVWRVSYTTFTVSKYWCYR; Cav1 (SD-Cav1)-DGIWKASFTTFTVTKYWFYR; for the nonscaffolding domain (NSD) peptide: Cav3 (NSD-Cav3)-NRDPKNINEDI-VKVDFEDVIAEPEG; Cav1 (NSD-Cav1)-NRDPKHLNDDVVKID-FEDVIAEPEG. Briefly, purified PTP1B (0.022 units) was incubated with increasing concentrations of Cav peptide (0, 0.63, 1.25, 2.5, 5, and 10 M) at room temperature for 10 min, followed by the addition of the enzyme substrate and an additional 15-min incubation. PTP1B activity was determined by spectrophotometry.
RESULTS
Overexpression of Cav3 in the liver. The liver expressed relatively small amounts of endogenous Cav1, and little Cav3 was detected by immunoblotting mouse liver homogenates. Using the Cav3 adenovirus (1.0 ϫ 10 7 PFU), Cav3 expression in liver homogenates was comparable to that of endogenous Cav3 in the skeletal muscle ( Fig. 2A) , another major organ involved in regulating glucose metabolism that abundantly expresses Cav. With this amount of adenovirus, the expression of Cav3 peaked at day 4 postinjection and plateaued at least until day 6 (Fig. 2B) . The gene delivery of Cav3 was restricted to the liver, and there was no increase in Cav3 expression in the other organs such as skeletal muscles or adipose tissues (Fig. 2,  C and D) . Despite Cav3 overexpression, the protein expression of IR-␤ as well as other molecules involved in IR signaling such as IRS, phosphatidylinositol 3-kinase (PI3K), Akt, or PTP1B were unchanged (Fig. 2E) , suggesting that Cav3 does not regulate the protein expression of these molecules, at least, in the liver. The subcellular distribution of exogenous Cav3 and endogenous IR-␤, as determined by sucrose gradient fractionation of liver tissues, was unchanged and similar to that of endogenous Cav1 (Fig. 2F) , and insulin binding assays using intact hepatic cells revealed no changes in B max [GFP vs. Cav3: 4.2 Ϯ 0.1 vs. 4.3 Ϯ 0.2, n ϭ 4, P ϭ not significant (NS)] or K d (GFP vs. Cav3: 58.4 Ϯ 0.1 vs. 58.9 Ϯ 0.4 fmol, n ϭ 4, P ϭ NS) with Cav3 gene transfer, suggesting that Cav3 gene transfer did not alter the caveolar and/or the cell surface localization of IR.
Cav3 gene transfer is associated with increased glycogen synthesis in the liver. Because one of the most important actions of insulin is to promote glycogen synthesis in tissues (23), we examined whether Cav3 gene transfer changed the glycogen content in the livers of diabetic obese mice and found that it was significantly increased in mice with Cav3 gene transfer (Fig. 3A) . Fat deposition was similar in the livers of diabetic obese mice with Cav3 gene transfer and GFP gene transfer, indicating that it was caused by a high-fat diet and not by Cav3 overexpression. The increase in glycogen content in mice with Cav3 gene transfer was accompanied by a decrease in protein expression of the cytosolic form of phosphoenolpyruvate carboxykinase (PEPCK) (Fig. 3C ). This enzyme catalyzes the first irreversible reaction in gluconeogenesis, and the activity of PEPCK is proportional to the amount of this enzyme, which is regulated by insulin (15) . These findings agree with the concept that insulin signals were enhanced in the liver after Cav3 gene transfer. In contrast, the expression of glucokinase (Gck) and Foxo1 activity remained changed (Fig.  3, D and E) .
Abnormal serum lipid concentrations were not improved, potentially because the duration of Cav3 overexpression was short (Fig. 3F) . Liver triglycerides and serum leptin concentrations were also unchanged (data not shown). Histology and periodic acid-Schiff (PAS) staining demonstrated that the purple staining of glycogen was greater in mice with Cav3 gene transfer (Fig. 3G) . There was no staining of glycogen when tissues were pretreated with diastase. We also performed oil red O staining and scored the degree of lipid accumulation in hepatic tissues (16) . However, there was no significant difference in the lipid score between GFP and Cav3 groups (GFP 1.94 Ϯ 0.34, Cav3 ϭ 2.14 Ϯ 0.25, n ϭ 7-8, P ϭ NS) (Fig. 3B) .
Similarly, the expression of enzymes involved in lipogenicrelated enzymes, such as fatty acid synthase (FAS), sterol regulatory element-binding protein-1, phosphodiesterase 3B, acetyl CoA carboxylase, and liver X receptor, was not significantly different between GFP and Cav3 groups (data not shown).
Cav3 gene transfer improved insulin signals in diabetic obese mice. Cav3 gene injection into diabetic obese mice not only increased the hepatic glycogen content but also improved impaired glucose metabolism. Although Cav3 gene transfer did not alter food intake or body weight (data not shown), impaired glucose tolerance test performance as well as FBG levels (GFP vs. Cav3: 213.3 Ϯ 11.2 vs. 175.3 Ϯ 5.5 mg/dl, n ϭ 8, P Ͻ 0.05) were significantly improved (Fig. 4A) . There was no significant difference in glucose tolerance test performance between non-gene and GFP gene-transferred diabetic obese mice (data not shown). This improvement in glucose metabolism was most likely due to increased insulin action as demonstrated by the improved insulin tolerance test performance (Fig. 4B) . FBG levels remained lower in mice with Cav3 gene transfer than in control mice with GFP gene transfer, even 90 min after insulin challenge. During the glucose tolerance test, insulin levels were not changed by Cav3 gene transfer (Fig. 4C ) 
KKA
y mice, which have been widely used as a model of Type 2 diabetes (17), showed only a mild increase in fasting blood glucose concentrations (2), but a marked impairment in glucose tolerance test performance. However, when we injected the Cav3 gene into this mouse model, glucose tolerance test performance was significantly improved (Fig. 4D) . Therefore, the effect of Cav3 gene transfer on insulin signaling occurs in multiple diabetic mouse models.
Changes in hepatic tissue insulin signaling after Cav3 gene transfer. When whole homogenates of livers from diabetic obese mice with Cav3 gene transfer were examined, we found that IR-␤, IRS, and Akt phosphorylation was increased (Fig. 4,  E-G) , suggesting that IR signaling increased after Cav3 gene transfer compared with GFP gene transfer. Because the total protein levels of these molecules including IR-␤ were not increased, this effect was most likely due to the increased activity of IR-␤ itself. Because Cav3 gene transfer was restricted to the liver, it was also likely that hepatic Cav3 enhanced the response to insulin, leading to an overall improvement in whole body glucose metabolism. We also examined other relevant enzymes such as Gck, G6Pase, and F-1,6BP (Fig. 4, I-K) . The mRNA expression of Gck and G6Pase were increased in Cav3 group, suggesting transcriptional activation of these enzymes, while that of F-1,6BP was not changed. The activation of GSK3␤ was not changed either (Fig. 4H) .
Cav3 overexpression in hepatic cells. A similar enhancement in insulin signaling by Cav was observed in HepG2 cells, a cultured hepatic cell line. Two days after gene transfer, Cav3 was overexpressed in HepG2 cells to levels equivalent to that of endogenous Cav3 in skeletal muscles (data not shown). IR-␤ and IRS-1 phosphorylation was significantly enhanced at baseline, which was further increased with increasing concentrations of insulin (0 -100 nM) (Fig. 5, A and B) . The maximal activation of IRS-1 was significantly greater in Cav3 genetransferred cells, suggesting that IR kinase activity in response to insulin was increased by Cav3 overexpression, which confirmed our in vivo observations. At high concentrations (Ͼ10 nM), IR-␤ phosphorylation appeared saturated, while IRS-1 activation was further enhanced in a dose-dependent manner. The cellular content of glycogen was also increased at baseline (Fig. 5C) . We also examined the phosphorylation of insulinlike growth factor receptors (IGF-1R) in mice with Cav3 gene transfer because IR-␤ and IGF-1R are structurally similar and Cav3 may alter IGF-1R signaling (14) . However, the degree of IGF-1R phosphorylation was similar, suggesting that Cav3 specifically enhances IR-␤ (Fig. 5D) .
Caveolin-mediated inhibition of PTP1B activity. The activation of other downstream molecules such as extracellular signal-related kinase (ERK) and phosphatase and tensin homolog (PTEN) in the liver was not significantly different between mice that received Cav3 gene transfer and GFP gene transfer (data not shown). In contrast, it is known that phosphatases, such as PTP1B, can also potently regulate the activity of IR signals (8) . In addition, previous studies have demonstrated that PTP1B is present in caveolae (22, 30) and physically interacts with Cav (6). We found that the expression of hepatic PTP1B was significantly increased in diabetic obese mice (Fig. 6A) and that overexpressed Cav3 coimmunoprecipitated with PTP1B in the liver (Fig. 6B) . Furthermore, we found that Cav3 inhibited the activity of PTP1B. A SD-Cav3 peptide, which is known to mimic Cav3 (26) , inhibited the activity of purified PTP1B in a dose-dependent manner in vitro, while a similar peptide derived from non-SD Cav3 had no effect (Fig.  6C) . We also found that a peptide from SD-Cav1 similarly inhibited the activity of PTP1B activity while a NSD-Cav1 had no effect (Fig. 6D) . These results suggest that Cav3 as well as Cav1 directly interacts with and inhibits the activity of PTP1B. Furthermore, this inhibition may be potentiated in the livers of obese mice where PTP1B expression was increased. 
DISCUSSION
Adenovirus-mediated gene transfer of Cav3 to the liver resulted in increased hepatic glycogen synthesis accompanied by decreased hepatic PEPCK protein levels. Insulin sensitivity, as measured by changes in FBG levels upon insulin injection and glucose tolerance test performance, were improved after Cav3 gene transfer in obese diabetic mice. A similar improvement in glucose metabolism was observed in KKA y mice. Overexpression of Cav3 in cultured hepatic cells led to increased phosphorylation of IR-␤ and IRS in response to insulin stimulation with increased glycogen synthesis at baseline. Therefore, our findings suggest that Cav enhances insulin signals in the liver. The molecular mechanism of this enhanced insulin action may involve direct stimulation of IR by Cav, because a similar mechanism was previously proposed using purified IR and Cav peptides in vitro (30) . Although we do not know the extent of caveolin-mediated inhibition of PTP1B activity in vivo, the physical interaction between PTP1B and caveolin has been reported in other studies (6) . Furthermore, several investigators have demonstrated the effect of caveolin peptide administration to regulate signaling activity in cells, suggesting that such interaction of caveolin peptide occurs in living cells as well (4, 12, 25, 31) .
Furthermore, as shown in the current study, direct inhibition of PTP1B by Cav may be another mechanism by which Cav enhances insulin signals. Obese diabetic mice showed an upregulation of hepatic PTP1B protein, and PTP1B activity was directly inhibited by a SD-Cav3 peptide. Increased expression of phosphatases in obesity was previously reported for other tissues (1) . A physical and functional interaction between Cav and PTP1B might be responsible for the slow recovery of glucose levels in insulin tolerance tests as well as for the marked phosphorylation of IR even at low concentrations of insulin (0 -1 nM) in mice with Cav3 gene transfer (Fig. 5A) . Together, Cav3 gene transfer may be a strategy to improve glucose metabolism in vivo.
Adipose and muscle tissues are the major target organs of insulin action that abundantly express Cav1 and Cav3, respectively. Cav may play an important role in these tissues because disruption of the Cav genes, either Cav1 or Cav3, markedly impairs adipose and muscular insulin signals (7, 22) . However, the role of Cav in insulin signals in the liver, another major target organ of insulin action, has been uncertain; the liver does not express abundant levels of Cav but has intact insulin signaling. Our findings have demonstrated that Cav can play an important role in insulin signals in the liver, particularly when overexpressed under pathological conditions, such as insulin resistance induced in diabetics by a high-fat diet.
Cav has been long considered a major inhibitor of growth signals and a tumor growth/proliferation suppressor (29) , except in prostate cancer (18) . Cav gene therapy has been proposed as a potential treatment to suppress tumor proliferation and/or metastasis in various cancers, such as breast cancer (29) . Our findings suggest, however, that Cav3 plays an opposite role in insulin signaling; it stimulates IR activity, leading to enhanced IR signals.
In conclusion, Cav3 may be a conditional but important regulator of glucose metabolism. The lack of Cav impaired insulin sensitivity in adipocytes and muscles where endogenous Cav is abundantly expressed (7, 22) . Although the liver does not express high levels of Cav under normal conditions, hepatic insulin signals remain intact. However, when insulin signals are impaired in diabetes, increased Cav expression in the liver improves glucose metabolism. The robust nature of our findings suggests that Cav, a membrane-anchoring protein, enhances IR signals.
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